TARGET: Acute Myeloid Leukemia (AML)

There are 200+ fully characterized patient cases with AML (all tumor/normal pairs, 100 with relapse sample as well) that make up the TARGET AML dataset, each with gene expression, tumor and paired normal copy number analyses, methylation and comprehensive next-generation sequencing to include whole genome sequencing, mRNA-seq and miRNA-seq. A subset of these cases will also have whole exome sequencing data available as well. There are additionally a large number of cases with partial molecular characterization making this a large and informative genomic dataset. Additionally, the TARGET AML cohort includes some highly aggressive subtypes including AML "induction failures." Upon diagnosis, AML patients without high-risk genetic markers undergo standard chemotherapy, called the primary induction phase. This phase lasts about 30 days and is designed to eliminate cancer cells. Success of treatment is measured by the percentage of myeloblasts, i.e. immature... (for more see dbGaP study page.)

构成TARGET AML数据集的是200余例经过完整分子特征鉴定的急性髓系白血病（AML）患者病例，所有病例均包含肿瘤与正常组织配对样本，其中100例还附带复发样本。每例样本均具备基因表达谱、肿瘤及配对正常组织的拷贝数分析数据、甲基化检测数据，以及涵盖全基因组测序（Whole Genome Sequencing, WGS）、mRNA-seq和miRNA-seq的全面下一代测序（Next-Generation Sequencing, NGS）数据。部分病例还额外拥有全外显子组测序（Whole Exome Sequencing, WES）数据。此外，尚有大量仅完成部分分子特征鉴定的病例，使得该数据集成为规模庞大且信息丰富的基因组学数据集。此外，TARGET AML队列还包含若干极具侵袭性的AML亚型，其中包括AML“诱导治疗失败”亚型。确诊后，未检出高危遗传标志物的AML患者将接受标准化疗，该方案被称为初始诱导治疗阶段。该阶段持续约30天，旨在清除体内癌细胞。治疗效果通过成髓细胞（myeloblasts，即未成熟髓系细胞）的占比进行评估……（更多详情请参见dbGaP研究页面）

搜集汇总

背景与挑战

背景概述

该数据集是一个关于急性髓系白血病(AML)的大型基因组研究项目，包含200多个完整表征的病例，涵盖基因表达、拷贝数分析、甲基化和下一代测序等多维度数据。特别关注包括AML'诱导失败'在内的高度侵袭性亚型，为AML研究提供了丰富资源。